(Q51180919)

31 March 2018

title

Bayesian methods for design and analysis of safety trials. (English)

1 reference

31 March 2018

John Scott

6

0 references

James D. Stamey

object named as

James D Stamey

7

0 references

author name string

Karen L Price

1

1 reference

31 March 2018

H Amy Xia

2

1 reference

31 March 2018

Mani Lakshminarayanan

3

1 reference

31 March 2018

David Madigan

4

1 reference

31 March 2018

David Manner

5

1 reference

31 March 2018

Laura Thompson

8

1 reference

31 March 2018

publication date

30 July 2013

1 reference

31 March 2018

Pharmaceutical Statistics

published in

1 reference

31 March 2018

volume

13

1 reference

31 March 2018

issue

1

1 reference

31 March 2018

page(s)

13-24

1 reference

31 March 2018

Comparison of Bayesian with group sequential methods for monitoring clinical trials.

cites work

1 reference

A unified method for monitoring and analysing controlled trials.

21 January 2018

1 reference

21 January 2018

Bayesian clinical trials

1 reference

Interpretation and choice of effect measures in epidemiologic analyses

21 January 2018

1 reference

Choice of effect measure for epidemiological data

21 January 2018

1 reference

Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes

21 January 2018

1 reference

Bayesian hierarchical modeling for detecting safety signals in clinical trials

21 January 2018

1 reference

Analyses of longitudinal, hospital clinical laboratory data with application to blood glucose concentrations.

21 January 2018

1 reference

Semiparametric bayesian testing procedure for noninferiority trials with binary endpoints

21 January 2018

1 reference

Robust Bayesian sample size determination in clinical trials

21 January 2018

1 reference

A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder

21 January 2018

1 reference

Evidence-based sample size calculations based upon updated meta-analysis

21 January 2018

1 reference

Sequential methods for random-effects meta-analysis

21 January 2018

1 reference

Meta-analysis in genome-wide association studies

21 January 2018

1 reference

Safety monitoring in clinical trials

21 January 2018

1 reference

Bayesian adaptive design for device surveillance.

21 January 2018

1 reference

Predicting accrual in clinical trials with Bayesian posterior predictive distributions.

21 January 2018

1 reference

Predicting analysis times in randomized clinical trials

21 January 2018

1 reference

Weibull prediction of event times in clinical trials.

21 January 2018

1 reference

Predicting event times in clinical trials when treatment arm is masked.

21 January 2018

1 reference

Bayesian and mixed Bayesian/likelihood criteria for sample size determination

21 January 2018

1 reference

Sample size and the probability of a successful trial

21 January 2018

1 reference

Bayesian design of noninferiority trials for medical devices using historical data

21 January 2018

1 reference

Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes

21 January 2018

1 reference

Adaptive increase in sample size when interim results are promising: a practical guide with examples

21 January 2018

1 reference

A Bayesian approach to the assessment of inhibitor risk in studies of factor VIII concentrates

21 January 2018

1 reference

Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant fa

21 January 2018

1 reference

Assurance in clinical trial design

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PST.1586

1 reference

31 March 2018

1 reference

31 March 2018